6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
Just now	Quarterly Activities Report - March 2026
Just now	Appendix 4C and Quarterly Activities Report - March 2026
19m ago	Landis+Gyr Announces Sale of Rhebo to Everfield
20m ago	Lazard to Acquire Campbell Lutyens, Creating the Global Leader in Private Capital Advisory
30m ago	2026 ESMO GC \| Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

About

Immunovant Inc (NASDAQ:IMVT) — investor relations, events, news, and company updates on 6ix.

Latest News

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Financials

Revenue

$0

Market Cap

$5.22 B

EPS

-2.67

Community Chat

Ask AI